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We describe a family with a novel, inherited AXIN2 mutation
(c.1989G>A) segregating in an autosomal dominant pattern
with oligodontia and variable other findings including colonic
polyposis, gastric polyps, a mild ectodermal dysplasia phenotype
with sparse hair and eyebrows, and early onset colorectal and
breast cancers. This novel mutation predicts p.Trp663X, which is
a truncated protein that is missing the last three exons, including
the DIX (Disheveled and AXIN interacting) domain. This non-
sense mutation is predicted to destroy the inhibitory action of
AXIN2 on WNT signaling. Previous authors have described an
unrelated family with autosomal dominant oligodontia and a
variable colorectal phenotype segregating with a nonsense mu-
tation of AXIN2, as well as a frameshift AXIN2 mutation in an
unrelated individual with oligodontia. Our report provides
additional evidence supporting an autosomal dominant
AXIN2-associated ectodermal dysplasia and neoplastic
syndrome.  2011 Wiley-Liss, Inc.
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INTRODUCTION
Several inherited colorectal cancer syndromes result from germline
mutations in tumor suppressor or mismatch repair genes. These
include familial adenomatous polyposis (FAP) resulting from
germline APC mutations, MYH-associated polyposis resulting
from biallelic germline MYH mutations, and Lynch syndrome,
also known as hereditary nonpolyposis colorectal cancer syndrome,
resulting from mutations in one of four mismatch repair genes,
MSH2, MLH1, MSH6, or PMS2 [Lynch, 2008; Lindor, 2009]. These
syndromes often include extracolonic manifestations. However,
not all familial colon cancer can be attributed to these or other
known, rare conditions, suggesting that other uncharacterized
cancer syndromes and genes remain to be described.
Because mutations in several genes of the canonical WNT
pathway (i.e., APC, CTNNB1 which encodes B-catenin) have been
implicated in colorectal tumorigenesis, other genes in this pathway
may play a role in these uncharacterized families, including AXIN2.
Mutations in genes of the WNT signaling pathway that prevent
the degradation of B-catenin lead to tumorigenesis by upregulating
WNT signaling. Within the WNT pathway, AXIN2 acts as a
negative regulator by contributing to the assembly of the B-catenin
degradation complex [Polakis, 2007]. Somatic AXIN2 mutations
have been described in a variety of human cancers, including
colorectal cancers [Liu et al., 2000; Salahshor and Woodgett,
2005]. AXIN2 has also been independently implicated in tooth
agenesis and oral clefts [Mostowska et al., 2006; Callahan et al.,
2009; Letra et al., 2009].
Of particular interest is the description of a four-generation
Finnish kindred in which both oligodontia and a variable colorectal
phenotype segregated with a nonsense mutation in AXIN2 [Lammi
et al., 2004]. In this family, the oligodontia phenotype (defined
as congenital absence of six or more permanent teeth, third molars
excluded) was entirely penetrant in mutation carriers. No other
ectodermal findings such as those involving the nails, hair, or skin
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were described. The colorectal phenotype in this family was
variable. Six of the seven family members with oligodontia
had colorectal neoplasms, ranging from polyposis to colorectal
malignancy with no polyps. Lammi et al. [2004] also screened
oligodontia patients for AXIN2 mutations and identified a de
novo germline mutation in a 13-year-old boy with oligodontia.
Of note, the germline mutation in this patient was a 1-bp insertion
in exon 7 that was identical to a frameshift mutation described in
a colorectal cancer tissue [Liu et al., 2000].
We describe an unrelated family with an inherited AXIN2
mutation segregating in an autosomal dominant pattern with
oligodontia and variable other findings including colonic poly-
posis, gastric polyps, a mild ectodermal dysplasia phenotype with
sparse hair and eyebrows, and early onset colorectal and breast
cancers. This report provides additional clinical description of
and support for an autosomal dominant AXIN2-associated ecto-
dermal dysplasia and neoplastic syndrome.
CLINICAL REPORT
A 35-year-old woman presented for evaluation of a possible
ectodermal dysplasia syndrome due to a history of oligodontia,
including the congenital absence of >10 secondary teeth, and
a family history of oligodontia (Fig. 1A,B). The proband was
the product of a full-term, uncomplicated pregnancy with a
birth weight of 3,232 g. Her past medical history was notable
for intermittent nonbloody diarrhea, gastric reflux, peptic ulcer
disease, iron deficiency anemia, polycystic ovary disease, decreased
fertility, fibromyalgia, insulin resistance, fundic gland polyps, Sjogren
disease, anxiety, and depression. She reported normal body hair,
normal nails, and normal sweating. Previous evaluations included a
normal colonoscopy and upper endoscopy exams revealing multiple
fundic gland polyps at age 33 and 35, normal capsule endoscopy at age
34, and normal rheumatology and celiac sprue evaluations.
At the time of her visit, physical exam was notable for
hypognathia, malar hypoplasia, broad nasal bridge, very sparse
eyebrows, fine scalp hair, and slightly upslanting palpebral fissures.
Oropharyngeal exam was noted for a high palate, several missing
teeth with increased spacing and conical shaping of several teeth
(Fig. 1A). She was otherwise noted to have normal body hair
distribution, normal nails, and normal skin. Review of photographs
from age 4 to 8 years showed sparse eyebrows, slightly upslanting
palpebral fissures, and thin upper vermillion (Fig. 1C).
Her family history was notable for oligodontia, absent eyebrows,
sparse hair, colon polyps, early onset colon cancer, and early onset
breast cancer (Fig. 1B and Table I). The proband’s mother (II-2) had
oligodontia with absence of most of her secondary teeth. She began
colonoscopic screening at age 60 and was found to have >100
adenomatous polyps requiring a sigmoid colectomy at age 60 and
a right hemicolectomy at age 62. She was evaluated in our clinic and
was also noted to have soft skin with particularly scant body hair,
minimal axillary hair, short eyelashes, and very sparse eyebrows,
especially laterally.
The proband had two maternal aunts, including one (II-1) with
oligodontia, breast cancer diagnosed at age 44, metachronous colon
cancers diagnosed at age 50 and 59, and five adenomatous polyps
of the transverse and ascending colon at age 69. The other maternal
aunt (II-3) had a reported history of colon polyps, oligodontia,
absent eyebrows, and sparse hair. Confirmation of her history
was not available. The index patient’s sister (III-2) had no dental
or other ectodermal findings and had not undergone endoscopic
screening. One cousin (III-1) also had no dental or ectodermal
findings and had normal colon screening at age 41. The proband’s
maternal grandmother (I-2) died at age 97 with a reported history
FIG. 1. Oligodontia phenotype and pedigree. A: Panoramic radiograph demonstrating proband’s congenital absence of teeth 2, 7, 10, 15, 18, 23, 24, 25,
26, 27, and 31. B: Autosomal dominant inheritance of oligodontia, c.1989A>G, and variable colorectal phenotype. C: Photographs of the proband at
age 4 and 8 years showing sparse eyebrows, slightly upslanting palpebral fissures, and thin upper vermillion.
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of oligodontia, absent eyebrows, and sparse hair, and no known
history of colon polyps or cancers.
METHODS
Informed consent and blood samples were obtained from
the patient, her sister (III-2), mother (II-2), one maternal aunt
(II-1), and one maternal cousin (III-1) under the Institutional
Review Board approved University of Michigan Cancer Genetics
Registry. Bidirectional direct sequencing of known AXIN2 exons
and flanking intronic regions was performed on the proband.
Bidirectional sequencing of exon 7 and flanking intronic regions
was performed in the other study participants. The proband’s
mother (II-2) also underwent clinical genetic testing of the APC
gene including sequence analysis of exons 1–14 and the 50 end of
exon 15, protein truncation testing for mutations in exon 15,
and gene dosage analysis (MLPA) to test for the presence of large
deletions, duplications, and other genomic rearrangements. The
proband’s mother (II-2) also under went clinical testing for the
p.Tyr165Cys and p.Gly382Asp mutations of the MYH genes by a
PCR-based analysis (restriction enzyme digest).
The AXIN2 DNA sequence (NCBI reference sequence
NG_012142.1) was cloned from the DLD-1 cell line (ATCC,
Manassas, VA). The sequence was PCR amplified from cDNA
using primers specific to AXIN2 and inserted into the pCR2.1-
TOPO vector (Invitrogen, Carlsbad, CA). The c.1989G>A
mutation was introduced by site-directed mutagenesis using the
QuickChangeII site-directed mutagenesis kit (Stratagene, LaJolla,
CA). In vitro transcription and translation (TNT, Promega, Mad-
ison, WI) was performed following manufacturer’s instructions.
Biotinylated proteins were visualized following separation by
SDS–PAGE with streptavidin-conjugated HRP. HEK 293 cells were
transiently transfected with either a wild-type or c.1989G>A
AXIN2 construct using FugeneHD (Roche, Basel, Switzerland).
Cell lysates were analyzed by immunoblotting, following resolution
by SDS–PAGE, with a monoclonal AXIN2 antibody (Cell Signaling,
76G6, Danvers, MA).
RESULTS
Genetic testing in the proband showed a heterozygous c.1989G>A
gene alteration (p.Trp663X) (Fig. 2). This is a novel mutation that
introduces a stop codon at amino acid 663. The proband’s mother
(II-2) and maternal aunt (II-1) tested positive and her sister (III-2)
and cousin (III-1) tested negative (Table I and Fig. 1B). In vitro
transcription and translation of the c.1989G>A construct and
expression of the construct in HEK 293 cells produced an approxi-
mately 80 kDa protein representing a truncated AXIN2 product
missing the last three exons (Fig. 2B). The proband’s mother (II-2)
did not have a germline APC mutation identified and was negative
for the MYH p.Tyr165Cys and p.Gly382Asp mutations.
DISCUSSION
Our findings provide further evidence of an autosomal dominant
multisystem ectodermal and neoplastic phenotype associated with
a germline AXIN2 mutation. The novel mutation found in the
family reported here predicts p.Tyr663X. This truncated protein is
missing the last three exons, including the DIX domain. The DIX
(Disheveled and AXIN interacting domain) is required for AXIN2
homodimerization. Dimerization allows AXIN2 to act as a scaffold
for the assembly of protein complexes, in particular, the B-catenin
destruction complex. Formation of this complex is important for
the inhibition and negative feedback of WNT signaling. We predict
that loss of the DIX domain will have functional consequences and
destroy the inhibitory action of AXIN2 on WNT signaling.
Similar to the findings of Lammi et al. [2004] the oligodontia
phenotype in the family reported here is highly penetrant. In
addition, members of the family had a mild ectodermal dysplasia
phenotype characterized by absent or sparse eyebrows and body
hair. Furthermore, three of the four AXIN2 mutation carriers in
the family had a colorectal neoplasia, including one with a
modest number of adenomas (less than 10) who had two primary
colon cancers in her 50s (II-1), one with polyposis reminiscent
of FAP (II-2) and one with an unspecified number of colon
TABLE I. Summary of Clinical Findings and Mutation Analysis
ID number Age
Ectodermal







Unknown None Not tested
II-1 68 years Oligodontia At least five adenomas,





II-2 65 years Oligodontia, scant body hair, minimal
axillary hair, short eyelashes,
very sparse eyebrows
>100 adenomas, no upper
GI screening
None Positive
II-3 63 years Oligodontia, absent eyebrows,
sparse hair
Colon polyps (details unknown) None Positive
III-1 39 years Normal Normal colonoscopy None Negative
III-2 38 years Normal No GI screening None Negative
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polyps (II-3). The youngest mutation carrier in the family, the
proband (III-3), had normal colonoscopic findings in her mid 30s,
but was noted to have multiple fundic gland polyps. Given that
upper GI screening has not been performed in other mutation
carriers and that the proband’s fundic gland polyps could be
related to proton-pump inhibitor use, further exploration is needed
to determine if fundic gland polyps are related to AXIN2 mutations
[Choudhry et al., 1998].
The diagnosis of early onset breast cancer in one member of this
family (II-1) is intriguing given that others have hypothesized that
genetic variation influencing the expression of APC and AXIN2
influences breast cancer risk [Wang et al., 2008]. Supporting
evidence includes the finding that AXIN2 maps to a chromosomal
region at band 17q24 that has demonstrated allelic imbalance in
breast cancer samples, and an increased rate of breast cancer in
mouse models with upregulated WNT signaling [Zhang et al.,
2010]. Additionally, AXIN2 is involved in epithelial to mesenchy-
mal transitions in mammary epithelial cells, which is thought to be a
critical in the development of invasive and metastatic breast cancer
[Yook et al., 2006]. It is unclear if the observed development of early
onset breast cancer in one member of this kindred is related to the
germline AXIN2 mutation identified. Further studies are needed to
substantiate a causal role.
AXIN2 mutations have also been associated with the develop-
ment of oral clefts, such as cleft lip and cleft palate (CL/CP). A recent
analysis of 75 families with CL/CP compared to controls found that
there was a significantly higher incidence of cancer in families with
CL/CP. In fact, the rates of breast and colon cancer in these families
were significantly higher [Menezes et al., 2009]. Additional studies
to examine the correlation of AXIN2 mutations with CL/CP
associated with an increased risk of breast or colon cancer are
needed to determine if a unique AXIN2-related syndrome of oral
clefs associated with an increased risk for cancer exists.
This report describes a second family with an AXIN2 mutation
cosegregating in an autosomal dominant pattern with oligodontia
and early onset cancers. In addition, this study extends the pheno-
typic spectrum associated with germline heterozygous AXIN2
mutations to include other ectodermal dysplasia features and
raises the possibility of an association with increased breast
cancer risk. Further studies are needed to determine the role of
AXIN2 mutations in inherited cancer predisposition and
better characterize the phenotype associated with this newly recog-
nized autosomal dominant AXIN2-associated ectodermal dysplasia
and neoplastic syndrome. Similar to other inherited cancer predis-
position syndromes, a careful family and personal medical history
is critical to developing a complete differential. Specifically,
cancer genetics professionals should inquire about the presence
of ectodermal phenotypes when assessing patients with familial
colorectal neoplasias. The co-occurrence of colorectal neoplasia,
including polyposis and colorectal cancer, with oligodontia,
other ectodermal dysplasia findings such as sparse hair and eye-
brows, or oral clefts should prompt an evaluation for AXIN2
mutations.
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